This week we discuss the latest news surrounding the novel coronavirus, including the WHO's decision to declare the virus a global emergency; A new triple combo therapy in type 2 diabetes; Updated Tdap vaccination recommendations; An FDA warning regarding serious clozapine side effects; And news of possible cybersecurity vulnerabilities with certain patient monitoring devices.

This week we cover the CDC coronavirus health advisory; A possible oral influenza vaccine; A new treatment to reduce the risk of MACE; An FDA Committee vote; And the first approved treatment for thyroid eye disease.

This week we cover the approval of a cocaine nasal solution; 23andMe's entry into the drug development; The recall of an epilepsy and bipolar treatment; A new nasal spray for seizure patients; And the weight loss drug that may be linked to cancer.

In our first episode of 2020 we cover new management guidelines in osteoarthritis; Recommendations for the use of testosterone therapy; The best diets for 2020; Two drug recalls; And a new drug approved for the treatment of migraines.

Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60's; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis.

MPR Weekly Dose Podcast: Episode 14 by MPR Weekly Dose

This week on the Weekly Dose we talk about the first lung transplant due to vaping-related illness; A new approval for patients with beta thalassemia; Opioids in osteoarthritis; A new, free test to help diagnose COPD; and news of a potential new therapy for hypercholesterolemia.

This week we talk about NDMA findings in ranitidine products; Approval of a new flu vaccine; The return of an antiarrhythmic agent; A new treatment for H. pylori infection; and the risk of biotin interference in test results which could lead to missed diagnoses.

This week we talk about the recall of an anti-anxiety med; Possible withdrawal of Makena; New MS treatment approved; IUD approved for up to six years; and time of day when meds taken could affect CVD risk.

This week we talk about the resurrection of Biogen's novel Alzheimer treatment; A "landmark" approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson's baby powder recall.